Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Branebrutinib by Bristol-Myers Squibb for Primary Sjogren's Syndrome: Likelihood of Approval
Branebrutinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...